Recent Finacing
Recent Raise
Tactiva Therapeutics is a Buffalo-based development-stage immuno-oncology company developing DEACT, an engineered CD4/CD8 adoptive T-cell platform that supplies durable helper CD4 cells to support CD8 TCR-transduced effector T cells.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
